A randomized, double-blind, multicenter study comparing a starting dose of 100 IU or 200 IU of recombinant follicle stimulating hormone (Puregon®) in women undergoing controlled ovarian hyperstimulation for IVF Treatment
Journal of Assisted Reproduction and Genetics, ISSN: 1058-0468, Vol: 22, Issue: 2, Page: 81-88
2005
- 22Citations
- 31Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations22
- Citation Indexes20
- 20
- CrossRef11
- Clinical Citations1
- PubMed Guidelines1
- Policy Citations1
- Policy Citation1
- Captures31
- Readers31
- 31
Article Description
Purpose: To compare the efficiency and efficacy of two starting doses of recombinant FSH (follitropin-β, Puregon) in women undergoing IVF treatment. Methods: This prospective, randomized, double-blind, multicentric (N = 6) study included 192 women undergoing IVF using the long protocol of GnRH agonist who received either 100 IU or 200 IU of r-FSH per day. Gonadotropin dose adjustment was allowed after day 4 of stimulation. Results: The average (SD) number of oocytes retrieved was 10.9 (5.4) and 12.2 (5.6) in the 100 IU and 200 IU group respectively (p = 0.067). The total doses of Puregon administered were 1887 IU and 2559 IU in the 100 IU and 200 IU group respectively. The number of transferable embryos, and the rates of pregnancies, cancelled cycles, miscarriages and adverse events including OHSS were comparable between the two groups. Conclusions: Women undergoing IVF have similar outcomes whether recombinant FSH is commenced in a dose of 100 IU or 200 IU for the first 4 days of stimulation. © 2005 Springer Science+Business Media, Inc.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=16844375320&origin=inward; http://dx.doi.org/10.1007/s10815-005-1497-1; http://www.ncbi.nlm.nih.gov/pubmed/15844733; http://link.springer.com/10.1007/s10815-005-1497-1; http://www.springerlink.com/index/10.1007/s10815-005-1497-1; http://www.springerlink.com/index/pdf/10.1007/s10815-005-1497-1; https://dx.doi.org/10.1007/s10815-005-1497-1; https://link.springer.com/article/10.1007/s10815-005-1497-1
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know